By Business & Finance 
Veterinary biologics company Nexvet Biopharma’s new development and manufacturing facility in Tullamore was officially opened today.
BioNua, a wholly owned subsidiary of Nexvet Biopharma, runs business operations at the premises, and has undertaken extensive refurbishment transforming it into a state-of-the-art facility dedicated to the emerging area of therapeutic veterinary biologics.
BioNua has a 10-year lease on the facility with an option to purchase the building, located in the IDA Business and Technology Park in Tullamore.
Securing a significant development and manufacturing facility and building BioNua’s capabilities is a major step forward for Nexvet’s plan to assume full internal control of its manufacturing.
Nexvet intends for BioNua to meet the company’s anticipated future global clinical and commercial needs for drug substance production in the high growth area of veterinary therapeutics.
The creation of BioNua has added to Nexvet’s vertical integration in animal health biopharmaceuticals, with research, drug development, manufacturing, clinical development and regulatory affairs now all managed internally.
Nexvet CEO Mark Heffernan said: “We are delighted with the rapid progress made by the dedicated BioNua team in internalising our manufacturing and preparing to supply Nexvet’s clinical trials. We have sourced outstanding talent for the BioNua team and installed state-of-the-art infrastructure. The compelling advantages of biologic therapies for chronic conditions in companion animals underpin Nexvet’s long-term vision for transforming animal medicine.”
CEO of IDA Ireland Martin Shanahan added: “It’s great to see the official opening today of this dedicated veterinary biologics facility in Ireland. IDA is delighted to have assisted in the creation of this high-value research development and innovation investment in a key regional location. This facility assists IDA market the Midlands region as a compelling location for foreign direct investment to potential client companies around the world. I wish Mark and his team every success here.”
